POMEZIE, Italy, October 20, 2022 /PRNewswire/ — Alfasigma SpA has completed the acquisition of SOFAR SpA, officially beginning the process of integrating the two companies.

The transaction, which was launched last August and was expected to be finalized in October 2022took place successfully in full compliance with the planned schedule.

Alfasigma is one of the leading multinational pharmaceutical companies with a turnover of more than one billion euros in 2021, R&D facilities in Bologna and Pomezia, 3 production plants in Italy and 2 abroad, around 3,000 employees, a local presence in 17 markets and an indirect presence in around 70 countries.

SOFAR is an Italian pharmaceutical company active in the research, production and marketing of medicines, medical devices and food supplements – with a long tradition and well known to professionals and patients – with a turnover of more than 100 million, 150 references marketed in more than 10 therapeutic areas and 300 employees worldwide.

In addition, SOFAR brings 54 years of history in the field of gastroenterology and a product portfolio very complementary to that of Alfasigma.

This purchase,” said Stefano Golinelli, President of Alfasigmawill bring our company the ultimate consolidation in the Italian market and an even stronger concentration in the field of gastroenterology, thus adding to the ambitious growth strategy of our company and meeting the challenge strongly desired by my father, the Cavaliere Marino Golinelli, to always look to the future future“.

Both companies are reasonably inclined to innovation. SOFAR in particular has developed, through the Kilometro Rosso Science and Technology Park in Bergamo, a center of excellence in microbiota research, while Alfasigma is developing a portfolio of products focused on the gastrointestinal field.

The integration between the two companies, through the development of their respective scientific know-how, will enable an even more leading position in the gastrointestinal field, a field in which SOFAR achieves more than 80% of its sales.

Alfasigma has a clear objective in mind: to focus on innovation, to become increasingly stronger in the gastrointestinal field and to maximize the potential of the international market. We are one of the main multinational pharmaceutical companies with Italian capital, we start from a solid present that is at the same time full of potential for the future, with great opportunities for improvementyou”, explains Francesco Balestrieri Chairman and CEO of Alfasigma which adds “We want to be more international, more specialized and more focused on the gastroenterology field. We still have room to develop the current portfolio, starting with the internationalization of the Consumer Healthcare division. Physiological growth will be accompanied by major inorganic development globally and in Europe in order to develop our R&D pipeline in Gastro specialty areas. The goal is to more than double our revenues in 10 years“ notes the CEO.

The synergy between the two companies will lead to the expansion of Alfasigma’s product range by Italy and in foreign markets, by adding SOFAR products to its portfolio: Pentacol, Enterolactis and Gerdoff for the gastrointestinal field; Cistiflux and Siler for the gynecological/urological field.

For more information:

Logo –


Comments are closed.